CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
ixabepilonedrug
Likely dose
Ixabepilone given intravenouslyAI-extracted
Key inclusion· 7
  • ✓Histologically confirmed endometrial adenocarcinoma that is recurrent or persistent and not amenable to surgery, radiotherapy, or standard chemotherapy
  • ✓Measurable disease with at least 1 unidimensionally measurable lesion ≥20 mm by conventional techniques or ≥10 mm by spiral CT
  • ✓Received exactly 1 prior chemotherapy regimen for endometrial adenocarcinoma management
  • ✓GOG performance status 0-2
Key exclusion· 7
  • ✕No prior ixabepilone
  • ✕No more than 1 prior cytotoxic chemotherapy regimen allowed
  • ✕Sensory or motor neuropathy grade 2 or higher
  • ✕Active infection requiring antibiotics

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00095979
NCT00095979Phase 2Completed
CompareCT.gov

A Phase II Evaluation of Ixabepilone (BMS-247550) [NCI-Supplied Agent, NSC #710428]) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

National Cancer Institute (NCI)·interventional·Posted Nov 9, 2004·Updated Jul 24, 2019

In Brief

A Phase 2 clinical trial evaluating ixabepilone for Endometrial Adenocarcinoma and 2 related conditions. Completed, enrolled 52 participants across 1 site.

Detailed Summary

Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die. This phase II trial is studying how well ixabepilone works in treating patients with recurrent or persistent endometrial cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Stage IV Endometrial Carcinoma
CountriesUnited States
CollaboratorsGynecologic Oncology Group

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 9, 2004
Enrollment StartMay 1, 2005
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 21.6 years ago

Interventions

ixabepilonedrug

Given IV